- Home
- ACXP vs RDHL Comparison
ACXP vs RDHL Comparison
Compare ACXP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACXP | RDHL |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACXP | RDHL |
|---|---|---|
| Price | $2.56 | $1.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $143.67 | N/A |
| AVG Volume (30 Days) | ★ 84.9K | 60.0K |
| Earning Date | 11-12-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $2.62 | $1.01 |
| 52 Week High | $25.00 | $6.98 |
Technical Indicators
Market Signals| Indicator | ACXP | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 28.16 | 34.63 |
| Support Level | $3.98 | $1.10 |
| Resistance Level | $3.63 | $1.23 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 0.01 | 38.76 |
Price Performance
Historical ComparisonAbout ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.